User profiles for Shyrar Tanussiya
 | Shyrar Tanussiya RamuPhD student, University of Sri Jayewardenepura, Sri Lanka Verified email at fgs.sjp.ac.lk Cited by 196 |
Antibody and T cell responses to Sinopharm/BBIBP-CorV in naïve and previously infected individuals in Sri Lanka
…, D Guruge, D Jayathilaka, B Gunasekara, S Tanussiya… - MedRxiv, 2021 - medrxiv.org
Background As there are limited data of the immunogenicity of the Sinopharm/BBIBP-CorV
in different populations, antibody responses against different SARS-CoV-2 variants of …
in different populations, antibody responses against different SARS-CoV-2 variants of …
Persistence of antibody and T cell responses to the Sinopharm/BBIBP-CorV vaccine in Sri Lankan individuals
…, D Guruge, A Wijesinghe, B Gunasekera, S Tanussiya… - MedRxiv, 2021 - medrxiv.org
Background To determine the kinetics and persistence of immune responses following the
Sinopharm/BBIBP-CorV, we investigated immune responses in a cohort of Sri Lankan …
Sinopharm/BBIBP-CorV, we investigated immune responses in a cohort of Sri Lankan …
Immune responses to Sinopharm/BBIBP‐CorV in individuals in Sri Lanka
…, A Wijesinghe, B Gunasekera, S Tanussiya… - …, 2022 - Wiley Online Library
As there are limited data of the immunogenicity of the Sinopharm/BBIBP‐CorV in different
populations, antibody responses against different SARS‐CoV‐2 variants of concern and T cell …
populations, antibody responses against different SARS‐CoV‐2 variants of concern and T cell …
Seroprevalence of SARS-CoV-2 infection in the Colombo municipality region, Sri Lanka
…, T Ranasinghe, G Somathilake, S Tanussiya… - Frontiers in public …, 2021 - frontiersin.org
Background: As the Municipality Council area in Colombo (CMC) experienced the highest
number of cases until the end of January 2021, in Sri Lanka, we carried out a serosurvey prior …
number of cases until the end of January 2021, in Sri Lanka, we carried out a serosurvey prior …
Antibody and memory B cell responses to the dengue virus NS1 antigen in individuals with varying severity of past infection
ST Ramu, M Dissanayake, C Jeewandara, F Bary… - …, 2023 - Wiley Online Library
To further understand the role of NS1‐specific antibodies (Abs) in disease pathogenesis,
we compared neutralizing antibody levels (Nabs), NS1‐Ab levels, IgG antibody subclass …
we compared neutralizing antibody levels (Nabs), NS1‐Ab levels, IgG antibody subclass …
Antibody and T cell responses to a single dose of the AZD1222/Covishield vaccine in previously SARS-CoV-2 infected and naïve health care workers in Sri Lanka
…, G Somathilaka, D Madhusanka, S Tanussiya… - medRxiv, 2021 - medrxiv.org
Background In order to determine the immunogenicity of a single dose of the AZD1222/Covishield
vaccine in a real-world situation, we assessed the immunogenicity, in a large cohort of …
vaccine in a real-world situation, we assessed the immunogenicity, in a large cohort of …
Transmission dynamics, clinical characteristics and sero-surveillance in the COVID-19 outbreak in a population dense area of Colombo, Sri Lanka April-May 2020
…, PD Pushpakumara, S Tanussiya Ramu… - PloS one, 2021 - journals.plos.org
Background The transmission dynamics of SARS-CoV-2 varies depending on social distancing
measures, circulating SARS-CoV-2 variants, host factors and other environmental factors…
measures, circulating SARS-CoV-2 variants, host factors and other environmental factors…
Identifying an Immunodominant Epitope of Dengue Non-Structural Protein 1 (NS1) in Acute Secondary Dengue Infections for Vaccine Development or Development of …
Dengue infection is a rapidly emerging disease with no licensed treatment or vaccine
available. It is currently unclear whether antibody responses to dengue virus (DENV) NS1 are …
available. It is currently unclear whether antibody responses to dengue virus (DENV) NS1 are …
Immune responses following the first dose of the Sputnik V (Gam-COVID-Vac)
…, H Fernando, PD Pushpakumara, S Tanussiya… - 2021 - researchsquare.com
As the first dose of Gam-COVID-Vac, is currently used as a single dose vaccine in some
countries, we investigated the immunogenicity of this at 4 weeks (327 naïve individuals). 88.7% …
countries, we investigated the immunogenicity of this at 4 weeks (327 naïve individuals). 88.7% …
[CITATION][C] Antibody and T cell responses to Sinopharm/BBIBP-CorV in naïve and previously infected individuals in Sri Lanka (preprint)
…, D Guruge, D Jayathilaka, B Gunasekara, S Tanussiya… - 2021
